Overview
Subcortical leukoencephalopathy refers to a spectrum of disorders characterized by white matter damage in subcortical regions, often due to chronic hypoperfusion and arteriolosclerosis, impacting cognitive and motor functions 1.Diagnosis
Immunohistochemical markers: Elevated BMP4 signaling in white matter lesions compared to controls may indicate disease pathology 1.
Imaging: MRI often reveals characteristic white matter hyperintensities on T2-weighted sequences.
Clinical assessment: Cognitive testing and neurological examination to evaluate cognitive decline and motor deficits.Management
Statins: Pravastatin may improve cerebral vasomotor reactivity, potentially slowing disease progression; dose 20 mg daily 2.
Vasoreactivity enhancement: Monitoring and enhancing cerebral blood flow dynamics through pharmacological interventions like pravastatin 2.Special Populations
Elderly: Pravastatin treatment shows efficacy in elderly patients with subcortical small-vessel disease, suggesting broader applicability 2.Key Recommendations
Consider pravastatin therapy (20 mg daily) to enhance cerebral vasomotor reactivity in patients with subcortical small-vessel disease (Evidence: Moderate) 2.
Evaluate BMP4 signaling in pathological specimens to aid in understanding disease mechanisms and potential therapeutic targets (Evidence: Weak) 1.
Regularly assess cerebral blood flow dynamics using TCD to monitor disease progression and treatment efficacy (Evidence: Expert opinion) 2.References
1 Uemura MT, Ihara M, Maki T, Nakagomi T, Kaji S, Uemura K et al.. Pericyte-derived bone morphogenetic protein 4 underlies white matter damage after chronic hypoperfusion. Brain pathology (Zurich, Switzerland) 2018. link
2 Sterzer P, Meintzschel F, Rösler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001. link